Endothelial function, blood pressure control, and risk modification: impact of irbesartan alone or in combination
Giuseppe Derosa, Sibilla AT SalvadeoDepartment of Internal Medicine and Therapeutics, University of Pavia, Pavia, ItalyAbstract: Irbesartan, an angiotensin II type 1 receptor antagonist, is approved as monotherapy, or in combination with other drugs, for the treatment of hypertension in many countri...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2010-05-01
|
| Series: | Integrated Blood Pressure Control |
| Online Access: | http://www.dovepress.com/endothelial-function-blood-pressure-control-and-risk-modification-impa-a4466 |